Skip to search formSkip to main contentSkip to account menu

tolrestat

Known as: N-((5-(trifluoromethyl)-6-methoxy-1-naphthalenyl)thioxomethyl)-N-methylglycine, N-5-trifluoromethyl-6-methoxy-1-thionaphthoyl-N-methylglycine, Glycine, N-((6-methoxy-5-(trifluoromethyl)-1-naphthalenyl)thioxomethyl)-N-methyl- 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Cancer is a well-known and well-studied disease. There are environmental as well as genetic factors that trigger cancer. All… 
2017
2017
(56) References Cited U.S. PATENT DOCUMENTS 4,568,693 2/1986 Sestans ................................ 514/524 OTHER PUBLICATIONS… 
2016
2016
Aldosereductaseisaldo-ketoreductaseenzymethatconvertglucoseto sorbitol andfructosebypolyolpathway. Accumulationof sorbitol… 
2003
2003
The aim of this study was to establish the characteristic cataract changes that occur in diabetic dogs. Research was conducted on… 
2000
2000
The effect of Tolrestat, an aldose reductase inhibitor,on high glucose-induced actin disassembly in rat glomerular mesangial… 
1995
1995
Summary This was a surveillance study to evaluate the safety of tolrestat (200 mg/day) in the treatment of diabetic neuropathy… 
1986
1986
The disposition of the aldose reductase inhibitor tolrestat (T) was determined in the mouse, rat, dog, assemensis monkey, and man… 
1984
1984
Summary: An ultraviolet spectrophotometric method and a high-performance liquid chromatographic (HPLC) method were developed for…